Days af­ter Gilead yanks PI3K drug, In­cyte with­draws NDA for its own PI3K — say­ing con­fir­ma­to­ry tri­als would take too long

The FDA’s in­ten­si­fy­ing scruti­ny on ac­cel­er­at­ed ap­provals isn’t just putting pres­sure on drug­mak­ers with mar­ket­ed prod­ucts. It is al­so sub­tly re­shap­ing the reg­u­la­to­ry dy­nam­ics. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER